Amarin shares soar after FDA agrees to fast-track review of its prescription strength fish oil pill for heart patients - CNBC
Amarin shares soar after FDA agrees to fast-track review of its prescription strength fish oil pill for heart patients CNBCThe FDA plans to review Vascep within six months instead of the usual 10, with a decision on approval expected sometime in late September.